Signal Genetics signals $25m IPO plans
This article was originally published in Clinica
Another medtech initial public offering is in the offing: this time, molecular diagnostic specialist Signal Genetics hopes to raise around $25m by offering 2.3 million shares at $10-12 each. At the midpoint of this range, this would give Signal a market cap of $53m. The New York-based firm plans to list on the Nasdaq market under the ticker symbol SGNL. Founded in 2010, Signal booked sales of $4.3m in 2013, down 2% year-on-year; but narrowed its net loss to $2.4m from $7.6m in 2012.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.